Pacific Edge reports decline in cancer test volumes

Cancer diagnostics company, Pacific Edge, has reported a decline in test volumes for the three months ending Dec 31 2023.

The decrease in tests processed at its laboratories was primarily attributed to the reduction of the sales team in the second quarter of 2024.

The sales team, which was scaled back due to uncertainty over Medicare coverage for Cxbladder, now stands at 17, down from its peak of 34.

In the third quarter of 2024, the company processed 7,172 tests, representing a 15.9% decrease from the previous quarter.

This decline was led by a 17.7% drop in US test volumes.

Pacific Edge also cited seasonal factors and the impact of the restructure for the decrease in test volumes.